A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

NCT00983307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-small-cell Lung

Interventions

DRUG: Erlotinib
RADIATION: Hypofractionated Radiotherapy

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Collaborators

[object Object]